Eli Lilly & Co. and Avid Pharmaceuticals, the makers of the Alzheimer's imaging agent Amyvid, recently discussed the upcoming CMS draft decision on reimbursement for Amyvid and similar agents. Wei-Li Shao, senior director of Lilly's Alzheimer's business division, discussed three possible coverage decisions: continued non-coverage, coverage of amyloid PET imaging in full or coverage with evidence development. Shao said the decision could come between late June and the end of July. The companies said various groups including SNMMI have expressed support for CMS coverage.
Published in Brief: